Evidence map›Paper›PMID 29696533›Full record

ArticleJournal of cardiovascular translational research2018

Tirofiban Positively Regulates β1 Integrin and Favours Endothelial Cell Growth on Polylactic Acid Biopolymer Vascular Scaffold (BVS).

Arturo Giordano, Simona Romano, Nicola Corcione, Giacomo Frati, Giuseppe Biondi Zoccai, Paolo Ferraro, Stefano Messina, Stefano Ottolini, Maria Fiammetta Romano

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of cardiovascular translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Arturo GiordanoUnità Operativa di Interventistica Cardiovascolare, Presidio Ospedaliero Pineta Grande, Castel Volturno, Italy.
Simona RomanoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, via Pansini, 5, 80131, Naples, Italy.
Nicola CorcioneUnità Operativa di Interventistica Cardiovascolare, Presidio Ospedaliero Pineta Grande, Castel Volturno, Italy.
Giacomo FratiDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Giuseppe Biondi ZoccaiDepartment of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Paolo FerraroUnità Operativa di Interventistica Cardiovascolare, Presidio Ospedaliero Pineta Grande, Castel Volturno, Italy.
Stefano MessinaUnità Operativa di Interventistica Cardiovascolare, Presidio Ospedaliero Pineta Grande, Castel Volturno, Italy.
Stefano OttoliniCentro Medico Laboratorio Milano, Milan, Italy.
Maria Fiammetta RomanoDepartment of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, via Pansini, 5, 80131, Naples, Italy. mariafiammetta.romano@unina.it.ORCID 0000-0001-5557-7307
Presidio Ospedaliero · ITUniversity of Naples Federico II · ITCentro Diagnostico Italiano · ITIstituto Neurologico Mediterraneo · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An unexpectedly high incidence of thrombosis in patients that received the polylactic acid bioresorbable vascular scaffold (BVS) suggests a delayed/incomplete endothelial repair with this stent. The anti-platelet agent tirofiban stimulates endothelial cell migration and proliferation, mediated by VEGF production. We investigated the tirofiban effect on the migration and adhesion of endothelial cells to BVS, in vitro. We performed human umbilical endothelial cell (HUVEC) cultures in the presence of BVS. Tirofiban, similarly to VEGF, increased the ability of HUVEC to grow on the vascular scaffold, compared to unstimulated or abciximab-treated cells. Tirofiban increased HUVEC expression of β1 and β3 integrins along with collagen and fibronectin. A role for β1 integrin in the "pro-adhesive and -migratory" signals elicited by tirofiban was suggested by use of an anti-β1-blocking antibody that prevented poly-levo-lactic acid vascular scaffold colonization. Our study suggests that tirofiban may improve the outcomes of patients receiving BVS by accelerating stent endothelization.

Indexed as

Absorbable ImplantsStentsAbciximabCell MovementCell ProliferationCells, CulturedCollagenFibronectinsHumansHuman Umbilical Vein Endothelial CellsIntegrin beta1Integrin beta3Percutaneous Coronary InterventionPlatelet Aggregation InhibitorsPolyestersProsthesis DesignAbciximabCollagenFibronectinsIntegrin beta1Integrin beta3ITGB3 protein, humanPlatelet Aggregation InhibitorsPolyesterspoly(lactide)TirofibanVascular Endothelial Growth Factor AAdhesionBVSMigrationTirofibanβ1 integrin

Identifiers

PMID29696533
OpenAlexW2801654102

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.